#United States #ALS Research #Clearwater #Mitsubishi Tanabe #RADICAVA ORS

Mitsubishi Tanabe Pharma America to Present Eight ALS Research Posters at 2025 NEALS Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has made an exciting announcement regarding its participation at the 2025 Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Annual Meeting, where it will showcase eight research poster presentations that deal with the complexities of amyotrophic lateral sclerosis (ALS). This gathering is scheduled for October 7-10 in Clearwater, Florida, and will also be available online to expand accessibility.

MTPA’s commitment to advancing ALS research is evident, as Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, expressed enthusiasm about the varied presentations to be shared. He indicated the importance of the research in meeting unmet needs in ALS care and the urgency of delivering innovative solutions that can lead to improved patient outcomes.

Insights on RADICAVA ORS® (edaravone)

Among the critical research areas being highlighted are recent findings on RADICAVA ORS®, a treatment for ALS. Notably, fresh data on the safety profile and potential biomarkers tied to this medication will be presented. Noteworthy is a three-year pharmacovigilance study that analyzed over 12,000 U.S. ALS patients, showing no new safety concerns emerging from RADICAVA ORS use.

Further digging into treatment response, a prospective analysis of the neutrophil-to-lymphocyte ratio (NLR) will also examine its predictive value as a prognostic biomarker. Additionally, an encore analysis from Japan will juxtapose findings from the SUNRISE Japan study against the Japanese Consortium for ALS Research (JaCALS) registry, offering vital perspectives on long-term outcomes for ALS patients receiving edaravone.

Poster Highlights Include:

• - Neutrophil-to-Lymphocyte Ratio Analysis: Investigating potential correlations between baseline NLR and treatment responses, which will take place on October 8 from 4:30 p.m. to 6:30 p.m. EDT.
• - Safety Data with RADICAVA®: Summarizing a three-year update on safety for U.S. ALS patients, set for October 9 from 4:20 p.m. to 6:20 p.m. EDT.
• - Long-term Prognostic Studies: Evaluating the long-term efficacy of edaravone in ALS patients based on comparative data from SUNRISE Japan and JaCALS, also scheduled for October 9.

Exploring Digital Health Innovations

In an age where technology and health are increasingly intertwined, MTPA will also underline the potential role of digital health within ALS management. Three presentations will be focused on the evaluation of smartphone-based, at-home telespirometry methods aimed at improving patient care.

Patients receiving edaravone were monitored through a prospective six-month study, yielding enlightening findings concerning the ALS Functional Rating Scale-Revised (ALSFRS-R) as differences in decline rates were noted, particularly when accounting for non-invasive ventilation (NIV).

Notable Digital Health Posters Include:

• - At-Home Telespirometry Findings: Identifying a slower decline of ALSFRS-R scores in patients not requiring NIV will take place on October 8, from 4:30 p.m. - 6:30 p.m. EDT.
• - Smartphone Applications: Two separate studies evaluating the efficacy of at-home telespirometry using smartphone applications will also be presented on October 8, reporting enhanced patient engagement and better awareness of disease symptoms.

Addressing the Diagnostic Journey

It's crucial to highlight that the challenges surrounding ALS do not merely rest on the treatment phase. Insightful posters based on the Adelphi ALS Disease Specific Programme will reveal the obstacles faced by patients from the initial consultation to diagnosis. Typically, this phase spans approximately five months, with frequent cases of crucial misdiagnoses, leading to essential delays in care.

Main Findings from the Diagnostic Journey Research:

• - Challenges Faced: Significant financial implications for patients, with a notable reliance on caregiver support being documented – a point echoed in the research showing that over 90% of patients depend on caregivers, predominantly spouses or partners.
• - Poster Sessions: The analysis centers on real-world data from the U.S. population living with ALS and will take place in two sessions on October 8 and October 9, offering a comprehensive look into the burden of disease.

About RADICAVA ORS® (edaravone)

For clarity, RADICAVA ORS (edaravone) was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022, specifically for ALS treatment. MTPA continues to address the pressing need for such therapies, evidenced by RADICAVA ORS providing an alternative to IV administration – enhancing quality of life for patients.

To date, the U.S. implementation of RADICAVA ORS has positively impacted over 19,000 ALS patients, collectively nourishing over 2.5 million therapy days supervised by healthcare professionals.

There’s a profound commitment from Mitsubishi Tanabe Pharma America to improve the landscape of ALS care. By presenting at NEALS, they not only contribute towards scientific progress but also nurture hope for patients and their families who face the stark challenges presented by this relentless condition.

For those eager to gain insights or follow the unfolding discussions from the NEALS meeting, be sure to check their online resources for ongoing updates. The dedicated work from MTPA promises to shine a light on the path toward better understanding and treatment of ALS.